

Curriculum Vitae

Personal information

Charlotte Beudart

Work experience

Present

Sept 2023 – present

Associate Professor, Clinical Research, Department of Biomedical Sciences, Faculty of Medicine, University of Namur, Namur, Belgium

Past

April 2023- August 2023

Methodologist, European Respiratory Society, Lausanne, Switzerland (part time)

August 2020 – August 2023

Post-doctoral stay in Department of Health Services Research, University of Maastricht (part time)

August 2020 – August 2023

Scientific Coordinator, Physical Medicine and Sport Traumatology Department, University Hospital of Liege, CNRF (part time)

September 2016 - August 2023

Associate Lecturer, Public Health Sciences, University of Liège

December 2016 – July 2020

Post-doctoral researcher in the Department of Public Health, Epidemiology and Health Economics at the University of Liège

September 2015 – March 2016

6-month research study period in *MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK*. Translation and validation of the English version of the SarQoL® questionnaire.

October 2014 – October 2018

FNRS Fellow Assistant in the Department of Public Health, Epidemiology and Health Economics at the University of Liège

July 2012 – September 2014

Research Assistant in the Department of Public Health, Epidemiology and Health Economics at the University of Liège

Education and training

June 2012 – December 2016

PhD thesis Public Health, Epidemiology and Health Economics, University of Liège

Thesis title: "Contribution to the study of sarcopenia: definition, diagnosis and outcomes"

September 2009 – June 2012

Master in Public Health Sciences, Epidemiology and Health Economics

University of Liège, Faculty of Medicine

Dissertation: « Evaluation de l'impact d'un entraînement de trois mois par vibrotomie sur le risque de chute chez des patients résidant en maison de repos »

Highest Honours

September 2006 – June 2009

Bachelor of Executive Secretary work, medical option

Haute Ecole de la Province de Namur

Dissertation: « Le médicament, de la recherche moléculaire à la commercialisation »

Honours

September 2000 - June 2006

General Certificate of Secondary Education: Dutch language (4), Mathematics (6), Sciences (3), English language (4)

Institut Saint-Louis, Namur

Additional information

Publications

Publications as First author

1. Beaudart C, Brabant C, Alokail M, Reginster JY, Bruyère O. Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review. *Drugs*. 2025 Oct;85(10):1289-1306. doi: 10.1007/s40265-025-02234-5. Epub 2025 Sep 5.
2. Beaudart C, Musuamba F, Locquet M, Dogné JM, Douxfils J. [Hydroxychloroquine use during the first COVID-19 wave: a case study highlighting the urgent need to enhance research practices within the publication ecosystem](#). *Arch Public Health*. 2025 Apr 27;83(1):115
3. Beaudart C, Alcazar J, Aprahamian I, Batsis JA, Yamada Y, Prado CM, Reginster JY, Sanchez-Rodriguez D, Lim WS, Sim M, von Haehling S, Woo J, Duque G; Global Leadership Initiative in Sarcopenia (GLIS) group. Health outcomes of sarcopenia: a consensus report by the outcome working group of the Global Leadership Initiative in Sarcopenia (GLIS). *Aging Clin Exp Res*. 2025 Mar 22;37(1):100.
4. Beaudart C, Veronese N, Douxfils J, Thiyagarajan JA, Bolzetta F, Albanese P, Voltan G, Alokail M, Harvey NC, Fuggle NR, Rizzoli R, Reginster JY. PTH1 receptor agonists for fracture risk: a systematic review and network meta-analysis. *Osteoporos Int*. 2025 Mar 6.
5. Beaudart C, Cella D, Fielding RA, Rolland Y, Vellas B, Canevelli M; ICSFR Task Force. Patient-reported outcomes in sarcopenia: An ICSFR task force report. *J Frailty Aging*. 2025 Feb;14(1):100010
6. Beaudart C. The influence of physical activity on sarcopenia. *Lancet Healthy Longev*. 2024 Feb;5(2):e86-e87. doi: 10.1016/S2666-7568(23)00270-2.
7. Fuggle NR, Beaudart C*, Bruyère O, Abrahamsen B, Al-Daghri N, Burlet N, Chandran M, Rosa MM, Cortet B, Demonceau C, Dere W, Halbout P, Hiligsmann M, Kanis JA, Kaufman JM, Kurth A, Lamy O, Laslop A, Maggi S, Matijevic R, McCloskey E, Mobasheri A, Prieto Yerro MC, Radermecker RP, Sabico S, Al-Saleh Y, Silverman S, Veronese N, Rizzoli R, Cooper C, Reginster JY, Harvey NC. Evidence-Based Guideline for the management of osteoporosis in men. *Nat Rev Rheumatol*. 2024 Mar 14. doi: 10.1038/s41584-024-01094-9. Online ahead of print.
8. Beaudart C, Tilquin N, Abramowicz P, Baptista F, Peng DJ, de Souza Orlandi F, Drey M, Dzhus M, Fábrega-Cuadros R, Fernandez-Garrido J, Laurindo LF, Gasparik AI, Geerinck A, Emin G, Iacob S, Kilaité J, Kumar P, Lee SC, Lou VWQ, Mahmoodi M, Matijevic R, Matveeva MV, Merle B, Montero-Erassquin B, Bhattoa HP, Safonova Y, Şimşek H, Topinkova E, Tsekoura M, Erdoğan T, Yoo JI, Yu R, Hiligsmann M, Reginster JY, Bruyère O. Quality of life in sarcopenia measured with the SarQoL questionnaire: A meta-analysis of individual patient data. *Maturitas*. 2024 Feb;180:107902
9. Beaudart C, Sharma M, Clark P, Fujiwara S, Adachi JD, Messina OD, Morin SN, Kohlmeier LA, Sangan CB, Nogue X, Cruz-Priego GA, Cavallo A, Cooper F, Grier J, Leckie C, Montiel-Ojeda D, Papaioannou A, Raskin N, Yurquina L, Wall M, Bruyère O, Boonen A, Dennison E, Harvey NC, Kanis JA, Kaux JF, Lewiecki EM, Lopez-Borbon O, Paskins Z, Reginster JY, Silverman S, Hiligsmann M. Patients' preferences for fracture risk communication: the Risk Communication in Osteoporosis (RICO) study. *Osteoporos Int*. 2023 Nov 13
10. Beaudart C, Li N, Boonen A, Hiligsmann M. Burden of osteoarthritis in the Netherlands: a scoping review. *Expert Rev Pharmacoecon Outcomes Res*. 2023 Sep 20:1-21.
11. Beaudart C, Demonceau C, Sabico S, Veronese N, Cooper C, Harvey N, Fuggle N, Bruyère O, Rizzoli R, Reginster JY. Efficacy of osteoporosis pharmacological treatments in men: a systematic review and meta-analysis. *Aging Clin Exp Res*. 2023 Jul 3. doi: 10.1007/s40520-023-02478-9.
12. Beaudart C, Reginster JY, Amuthavalli Thiyagarajan J, Bautmans I, Bauer J, Burlet N, Cesari M, Cherubini A, Cooper C, Cruz-Jentoft AJ, Dawson-Hughes B, Fielding RA, Harvey NC, Landi F, Laslop A, Maggi S, Montero-Erassquin B, Concepción PYM, Rolland Y, Rizzoli R, Visser M, Bruyère O. [Measuring health-related quality of life in sarcopenia: summary of the SarQoL psychometric properties](#). *Aging Clin Exp Res*. 2023 May 23. doi: 10.1007/s40520-023-02438-3. Online ahead of print.
13. Beaudart C, Galvanin M, Hauspy R, Clarsen BM, Demoulin C, Bornheim S, Van Beveren J, Kaux JF. French Translation and Validation of the OSTRC-H2 Questionnaire on Overuse Injuries and Health Problems in Elite Athletes. *Orthop J Sports Med*. 2023 Jun 8;11(6):23259671231173374
14. Beaudart C, Demonceau C, Reginster JY, Locquet M, Cesari M, Cruz-Jentoft AJ, Bruyère O. [Sarcopenia and health-related quality of life: A systematic review and meta-analysis](#). *J Cachexia Sarcopenia Muscle*. 2023 Jun;14(3):1228-1243. doi: 10.1002/jcsm.13243. Epub 2023 May 4
15. Ladang A, Beaudart C (co-first), Reginster JY, Al-Daghri N, Bruyère O, Burlet N, Cesari M, Cherubini A, da Silva MC, Cooper C, Cruz-Jentoft AJ, Landi F, Laslop A, Maggi S, Mobasheri A, Ormarsdottir S, Radermecker R, Visser M, Yerro MCP, Rizzoli R, Cavalier E. [Biochemical Markers of Musculoskeletal Health and Aging to be Assessed in Clinical Trials of Drugs Aiming at the Treatment of Sarcopenia: Consensus Paper from an Expert Group Meeting Organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases \(ESCEO\) and the Centre Académique de Recherche et d'Expérimentation en Santé \(CARES SPRL\), Under the Auspices of the World Health Organization Collaborating Center for the Epidemiology of Musculoskeletal Conditions and Aging](#). *Calcif Tissue Int*. 2023 Jan 12. doi: 10.1007/s00223-022-01054-z. Online ahead of print.
16. Beaudart C, Witjes M, Rood P, Hiligsmann M. [Medication administration errors in the domain of infusion therapy in intensive care units: a survey study among nurses](#). *Arch Public Health*. 2023 Feb 15;81(1):23.
17. Beaudart C, Drost RMWA, Evers SMAA, Paulus ATG, Hiligsmann M. [Associations between muscle mass/strength and healthcare costs/use for patients with cancer: A systematic literature review](#). *Cancer Treat Res Commun*. 2022;33:100633
18. Beaudart C, Silverman S, Gold DT, Williams SA, Weiss R, Hiligsmann M. [A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment](#). *Arch Osteoporos*. 2022 Apr 4;17(1):57. doi: 10.1007/s11657-022-01075-z.
19. Beaudart C, Boonen A, Li N, Bours S, Goemaere S, Reginster JY, Roux C, McGowan B, Diez-Perez A, Rizzoli R, Cooper C, Hiligsmann M. [Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment](#). *Osteoporos Int*. 2022 Jun;33(6):1335-1346. doi: 10.1007/s00198-022-06310-4. Epub 2022 Jan 26.
20. Beaudart C, Hiligsmann M, Li N, Lewiecki EM, Silverman S. [Effective communication regarding risk of fracture for individuals at risk of fragility fracture: a scoping review](#). *Osteoporos Int*. 2021 Sep 24. doi: 10.1007/s00198-021-06151-7.
21. Beaudart C, Demoulin C, Mehmeti K, Bornheim S, Van Beveren J, Kaux JF. [Validity and reliability of the French translation of the Identification of Functional Ankle Instability \(IdFAI\)](#). *Foot Ankle Surg*. 2021 Oct 7:S1268-7731(21)00202-2. doi: 10.1016/j.fas.2021.10.001.

22. Beaudart C, Bauer JM, Landi F, Bruyère O, Reginster JY, Hilgsmann M. Experts' preferences for sarcopenia outcomes: a discrete-choice experiment from a working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) in collaboration with the European Union of Geriatric Medicine Society (EUGMS). *Aging Clin Exp Res*. 2021 Mar 5. doi: 10.1007/s40520-021-01794-2
23. Beaudart C, Lengelé L, Leclercq V, Geerinck A, Sanchez-Rodriguez D, Bruyère O, Reginster JY. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. *Drugs*. 2020 Oct 19. doi: 10.1007/s40265-020-01423-8. Online ahead of print.
24. Beaudart C, Gillier M, Bornheim S, Van Beveren J, Bruyère O, Kaux JF. French Translation and Validation of the Victorian Institute of Sports Assessment for Gluteal Tendinopathy Questionnaire. *PM R*. 2020 Apr 23. doi: 10.1002/pmrj.12391. Online ahead of print.
25. Beaudart C, Bonnefoy M, Gilbert T, Paillaud E, Raynaud-Simon A, Guérin O, Jeandel C, Le Sourd B, Haine M, Ferry M, Rolland Y, Berrut G, Reginster JY, Bruyère O. [Quality of life and sarcopenic patients](#). *Geriatr Psychol Neuropsychiatr Vieil*. 2022 Feb 7. doi: 10.1684/pnv.2022.1009.
26. Beaudart C, Bruyère O, Geerinck A, Hajaoui M, Scafogliari A, Perkasas S, Bautmans I, Gielen E, Reginster JY, Buckinx F. Equation models developed with bioelectric impedance analysis tools to assess muscle mass: A systematic review. *Clin Nutr ESPEN*. 2020 Feb;35:47-62. doi: 10.1016/j.clnesp.2019.09.012. Epub 2019 Nov 15.
27. Beaudart C, Sanchez-Rodriguez D, Locquet M, Reginster JY, Lengelé L, Bruyère O. Malnutrition as a strong predictor of the onset of sarcopenia. *Nutrients* 2019 Nov 27;11(12). pii: E2883.
28. Beaudart C, Bruyère O, Cruz-Jentoft AJ, Vaquero-Pinto MN, Locquet M, Bauer J, Cooper C, Rolland Y, Dupuy C, Landi F, Reginster JY, Maggi S, Rizzoli R, Hilgsmann M; European Society for Clinical and Economic Aspect of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Patient's Engagement in the Identification of Critical Outcomes in Sarcopenia. *J Am Med Dir Assoc*. 2019 Oct 24. pii: S1525-8610(19)30654-1.
29. Beaudart C, Rolland Y, Cruz-Jentoft AJ, Bauer JM, Sieber C, Cooper C, Al-Daghri N, Araujo de Carvalho I, Bautmans I, Bernabei R, Bruyère O, Cesari M, Cherubini A, Dawson-Hughes B, Kanis JA, Kaufman JM, Landi F, Maggi S, McCloskey E, Petermans J, Rodriguez Mañas L, Reginster JY, Roller-Wirnsberger R, Schaap LA, Uebelhart D, Rizzoli R, Fielding RA. Assessment of Muscle Function and Physical Performance in Daily Clinical Practice : A position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Calcif Tissue Int*. 2019 Apr 10.
30. Beaudart C, Locquet M, Touvier M, Reginster JY, Bruyère O. Association between dietary nutrient intake and sarcopenia in the SarcoPhAge study. *Aging Clin Exp Res*. 2019 Apr 6.
31. C. Beaudart, T. Hagelstein, J. Van Beveren, B. Godon, O. Bruyère, JF. Kaux. [French translation and validation of the exercise-induced leg pain Questionnaire](#). *Disabil Rehabil*. 2018 Dec 3:1-6. doi: 10.1080/09638288.2018.1508512.
32. C. Beaudart, M. Locquet, S. Bornheim, JY. Reginster, O. Bruyère. French translation and validation of the sarcopenia screening tool SARC-F. *Eur Geriatr Med*
33. C. Beaudart, M. Locquet, JY. Reginster, L. Delandsheere, J. Petermans, O. Bruyère. [Quality of life in sarcopenia measured with the SarQoL®: impact of the use of different diagnosis definitions](#). *Aging Clin Exp Res*. 2017
34. C. Beaudart, J-Y. Reginster, A. Geerinck, M. Locquet, O. Bruyère. Current review of the SarQoL®: a health-related quality of life questionnaire specific to sarcopenia. 2017. *Expert Rev Pharmacoecon Outcomes Res*. 2017;17(4):335-341
35. C. Beaudart, E. Biver, O. Bruyère, C. Cooper, N. Al-Daghri, J-Y. Reginster, R. Rizzoli. [Quality of life assessment in musculoskeletal health](#). *Aging Clin Exp Res* 2017
36. C. Beaudart, V. Rabenda, M. Simmons, A. Geerinck, I. Araujo de Carvalho, J.-Y. Reginster, J. Amuthavalli Thiagarajan, Olivier Bruyère. Effects of protein, essential amino acids, B-hydroxy B-methylbutyrate, creatine, dehydroepiandrosterone and fatty acid supplementation on muscle mass, muscle strength and physical performance in older people aged 60 years and over. A systematic review of the literature. *J Nutr Health Aging* (2017).
37. C Beaudart, A Dawson, SC Shaw, NC Harvey, JA Kanis, N Binkley, J Y Reginster, R Chapurlat, DC Chan, O Bruyère, R Rizzoli, C Cooper, E M Dennison and the IOF-ESCEO Sarcopenia Working Group. Nutrition and physical activity in the prevention and treatment of sarcopenia: Systematic review. *Osteoporosis International*. *Osteoporos Int* 2017 ;28(6):1817-1833.
38. C. Beaudart, M. Zaaria, F. Pasleau, J-Y. Reginster, O. Bruyère. Health outcomes of sarcopenia: a systematic review and meta-analysis. *PLoS One*. 2017 17;12(1):e0169548. d
39. Beaudart C., Araujo de Carvalho I., Bautmans I., Bertiè MC., Brandi M., Bruyère O., Cavalier E., Cerreta F., Cesari M., Cherubini A., Cooper C., Fielding R., Gielen E., Kanis J., Landi F., McCloskey E., Petermans J., Reginster JY., Rizzoli R., Rolland Y., Visser M. Sarcopenia in daily practice: assessment and management. *BMC Geriatrics*. 2016, 16: 170.
40. C. Beaudart, M. Edwards, C. Moss, J-Y. Reginster, R. Moon, C. Parsons, C. Demoulin, R. Rizzoli, E. Biver, E. Dennison, O. Bruyère, C. Cooper. English translation and validation of the SarQoL®, a quality of life questionnaire specific for sarcopenia. *Age and Ageing* 2017 Mar 1;46(2):271-276.
41. C. Beaudart, JY Reginster, R. Rizzoli, Y. Rolland, I. Bautmans, E. Biver, J. Petermans, S. Gillain, N. Dardenne, O. Bruyère. Validation of SarQoL®, a specific health-related quality of life questionnaire for sarcopenia. *Journal of cachexia, Sarcopenia and Muscle*. 2017 Apr;8(2):238-244.
42. C. Beaudart, J-Y. Reginster, J. Petermans, O. Bruyère. Qualité de vie du patient sarcopénique: apport de l'étude liégeoise SarcoPhAge. *Gériatrie et Psychologie Neuropsychiatrie du Vieillessement* ,2015, Volume 13, Numéro 4.
43. C. Beaudart, E. Biver, JY Reginster, R. Rizzoli, Y. Rolland, I. Bautmans, J. Petermans, S. Gillain, J. Van Beveren, JM. Jacquemain, P. Italiano, N. Dardenne, O. Bruyère. Development of a self-administrated quality of life questionnaire for sarcopenia in elderly 65 years and older: the SarQoL. *Age Ageing*. 2015 Nov; 44(6): 960-966.
44. C. Beaudart, JY. Reginster, J. Petermans, S. Gillain, A. Quabron, M. Locquet, J. Slomian, F. Buckinx, O. Bruyère. Quality of life and physical components linked to sarcopenia: The SarcoPhAge study. *Exp Gerontol*. 2015 Sep;69:103-10
45. C. Beaudart, R. Rizzoli, O. Bruyère, J-Y. Reginster, E. Biver. Sarcopenia: Burden and challenges for Public Health. *Archives of public Health*. 2014, 72:45
46. C. Beaudart, JY. Reginster, J. Slomian, F. Buckinx, M. Locquet, O. Bruyère. Prevalence of sarcopenia: the impact of different diagnostic cut-off limits. *Journal of Musculoskeletal and Neuronal Interactions*. 2014;14(4):425-31.
47. C. Beaudart, JY. Reginster, J. Slomian, F. Buckinx, N. Dardenne, A. Quabron, C. Slangen, S. Gillain, J. Petermans, O. Bruyère Estimation of sarcopenia prevalence using various assessment tools. *Experimental Gerontology* 61 (2015) 31-37.
48. C. Beaudart, F. Buckinx, V. Rabenda, S. Gillain, E. Cavalier, J. Slomian, J. Petermans, JY. Reginster, O. Bruyère. The effects of vitamin D on skeletal muscle strength, muscle mass and muscle power: a systematic review and meta-analysis of randomized controlled trials. *J Clin Endocrinol Metab*. 2014 Nov;99(11):4336-45.
49. C. Beaudart, D. Maquet, M. Mannarino, M. Demonceau, J.M. Crielaard, J-Y. Reginster, O. Bruyère. Effects of 3 months of controlled whole body vibrations with low exposure period on the risk of falls among nursing home residents. *BMC Geriatrics*, 2013, 13:42

Publications as last author

-

1. Van Heden S, Chan YM, Baoubbou Z, Bruyère O, Reginster JY, Surquin M, Sanchez-Rodriguez D, Beaudart C. Towards a core outcome set for sarcopenia intervention studies: a scoping review identifying the most frequently reported outcomes across randomized controlled trials in sarcopenia. *Eur Geriatr Med*. 2025 Aug 12.
2. Mormont E, Jacques D, Saint-Hubert M, Sourdeau A, Beaudart C. Suicidal Behavior in Mild Cognitive Impairment and Dementia in the Old Adults: A Systematic Review and Meta-Analysis. *J Geriatr Psychiatry Neurol*. 2025 Aug 5;8919887251366639
3. Pellicori P, Douxfils J, Mentz RJ, Cleland JGF, Beaudart C. The Growing Demand for Peer Review: Current Challenges and Potential Reforms. *Br J Biomed Sci*. 2025 Jul 14;82:14930
4. Locquet M, Jacob S, Geets X, Beaudart C. Dose-volume predictors of cardiac adverse events after high-dose thoracic radiation therapy for lung cancer: a systematic review and meta-analysis. *BMC Cancer*. 2024 Dec 20;24(1):1556.
5. Douxfils J, Raskin L, Didembourg M, Donis N, Dogné JM, Morimont L, Beaudart C. Are natural estrogens used in contraception at lower risk of venous thromboembolism than synthetic ones? A systematic literature review and meta-analysis. *Front Endocrinol (Lausanne)*. 2024 Aug 16;15:1428597.
6. Doza GL, van Heden S, Oliveira Felix F, Singh V, Beaudart C. Impact of Interventions on Sarcopenia from the Perspective of Older Persons: A Systematic Literature Review. *J Frailty Aging*. 2024;13(3):224-232.

7. Demonceau C, Voz B, Bruyère O, Reginster JY, Beaudart C. Content validity of SarQoL, a quality of life questionnaire specific to sarcopenia. *Aging Clin Exp Res*. 2024 Apr 30;36(1):101.
8. Sanchez-Rodriguez D, Bruyère O, Surquin M, Reginster JY, Beaudart C. Towards a core outcome set (COS) for intrinsic capacity (IC) intervention studies in adults in midlife and beyond: a scoping review to identify frequently used outcomes and measurement tools. *Aging Clin Exp Res*. 2024 Mar 5;36(1):54.
9. Sanchez-Rodriguez D, Demonceau C, Bruyère O, Cavalier E, Reginster JY, Beaudart C. Intrinsic capacity and risk of death: Focus on the impact of using different diagnostic criteria for the nutritional domain. *Maturitas*. 2023 Oct;176:107817.
10. Bruyère O, Reginster JY, Beaudart C. [Lifestyle approaches to prevent and retard sarcopenia: A narrative review](#). *Maturitas*. 2022 Jul;161:44-48.
11. Locquet M, Sanchez-Rodriguez D, Bruyère O, Geerinck A, Lengelé L, Reginster JY, Beaudart C. [Intrinsic Capacity Defined Using Four Domains and Mortality Risk: A 5-Year Follow-Up of the SarcoPhAge Cohort](#). *J Nutr Health Aging*. 2022;26(1):23-29. doi: 10.1007/s12603-021-1702-7.
12. Anna Ariane, Purwita W. Laksmi, Siti Setiati, Rudy Hidayat, Suryo Anggoro Kusumo - Wibowo, Sumariyono, Fadhi Mahri, Caroline Tanadi h and Charlotte Beaudart, Validity and reliability of Sarcopenia Quality of Life® Indonesia questionnaire in sarcopenic patients. *Rheumatology & Autoimmunity*. March 2024.
13. Geerinck A, Locquet M, Hilgsmann M, Reginster JY, Bruyère O, Beaudart C. [Patients' preferences for quality-of-life aspects in sarcopenia: a best-worst scaling study](#). *Eur Geriatr Med*. 2021 Sep 25. doi: 10.1007/s41999-021-00563-8.
14. Declercq L, Schutz X, Kaux JF, Stoquart G, Thierry L, Vanderthommen M, Cayrol T, Selves C, Van Beveren J, Beaudart C. [Standard error of measurement and minimal detectable change of the French physical activity scale for individuals with physical disabilities](#). *Ann Phys Rehabil Med*. 2021 Nov 15;65(3):101583. doi: 10.1016/j.rehab.2021.101583.
15. Locquet M, Bruyère O, Lengelé L, Reginster JY, Beaudart C. Relationship between smoking and the incidence of sarcopenia: The SarcoPhAge cohort. *Public Health*. 2021 Mar 24;193:101-108. doi: 10.1016/j.puhe.2021.01.017.
16. Geerinck A, Locquet M, Bruyère O, Reginster JY, Beaudart C. Evaluating quality of life in frailty: applicability and clinimetric properties of the SarQoL® questionnaire. *J Cachexia Sarcopenia Muscle*. 2021 Feb 28. doi: 10.1002/jcsm.12687.
17. Geerinck A, Bruyère O, Locquet M, Reginster JY, Beaudart C. [Evaluation of the Responsiveness of the SarQoL® Questionnaire, a Patient-Reported Outcome Measure Specific to Sarcopenia](#). *Adv Ther*. 2018 Nov;35(11):1842-1858. doi: 10.1007/s12325-018-0820-z. Epub 2018 Oct 29.
18. Geerinck A, Locquet M, Reginster JY, Bruyère O, Beaudart C. Letter to the Editor: Discriminative Power of the Sarcopenia Quality of Life (SarQoL®) Questionnaire with the EWGSOP2 Criteria. *J Frailty Aging*. 2021;10(2):193-194. doi: 10.14283/jfa.2020.47.
19. Lengelé L, Moehlinger P, Bruyère O, Locquet M, Reginster JY, Beaudart C. Association between Changes in Nutrient Intake and Changes in Muscle Strength and Physical Performance in the SarcoPhAge Cohort. *Nutrients*. 2020 Nov 13;12(11):3485.
20. [Marta Dzhus](#) , [Maria Dzhus](#) , [Marta Masnyi](#) , [Myroslava Kulvyk](#) , [Halyna Mostbauer](#) , [Oleksiy Ivashkiykyv](#) , [Yaryna Boyko](#) , [Kateryna Cherchenko](#) , [Anton Geerinck](#) , [Jean-Yves Reginster](#) , [Olivier Bruyere](#) , [Charlotte Beaudart](#) . Cross-sectional Evaluation of the Sarcopenia Quality of Life (SarQoL) Questionnaire: Translation and Validation of its Psychometric Properties. *Ann Geriatr Med Res*. 2020 Jun;24(2):139-147.
21. Sanchez-Rodriguez D, Locquet M, Bruyère O, Lengelé L, Cavalier E, Reginster JY, Beaudart C. Prediction of 5-year mortality risk by malnutrition according to the GLIM format using seven pragmatic approaches to define the criterion of loss of muscle mass. *Clin Nutr*. 2020 Oct 8;S0261-5614(20)30519-7.
22. Sanchez-Rodriguez D, Locquet M, Reginster JY, Cavalier E, Bruyère O, Beaudart C. Mortality in malnourished older adults diagnosed by ESPEN and GLIM criteria in the SarcoPhAge study. *J Cachexia Sarcopenia Muscle*. 2020 Oct;11(5):1200-1211.
23. Alekna V, Kilaite J, Tamulaitiene M, Geerinck A, Mastaviciute A, Bruyère O, Reginster JY, Beaudart C. Validation of the Lithuanian version of sarcopenia-specific quality of life questionnaire (SarQoL®). *Eur Geriatr Med*. 2019 Oct;10(5):761-767.
24. Konstantynowicz J, Abramowicz P, Glinkowski W, Taranta E, Marcinowicz L, Dymitrowicz M, Reginster JY, Bruyere O, Beaudart C. Polish Validation of the SarQoL®, a Quality of Life Questionnaire Specific to Sarcopenia. *J Clin Med*. 2018 Oct 4;7(10):323.
25. Bahat G, Yilmaz O, Oren MM, Karan MA, Reginster JY, Bruyère O, Beaudart C. Cross-cultural adaptation and validation of the SARF-C to assess sarcopenia: methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. *Eur Geriatr Med*. 2018 Feb;9(1):23-28.

Publications as co-author

1. Bastijns S, Alabadi B, Barbosa-Silva TG, Beaudart C, Brockhattingen K, Lamers S, Piotrowicz K, Welch C, Cock AM, Perikias S. The Influence of Muscle Morphology on Oncological Outcomes: A Review. *J Frailty Sarcopenia Falls*. 2025 Sep 1;10(3):163-199. doi: 10.22540/JFSF-10-163. eCollection 2025 Sep.
2. McCloskey EV, Johansson H, Liu E, Åkesson KE, Anderson FA, Azagra-Ledesma R, Bager CL, Beaudart C, Bischoff-Ferrari HA, Biver E, Bruyère O, Cauley JA, Center JR, Chapurlat R, Christiansen C, Cooper C, Crandall CJ, Cummings SR, da Silva JAP, Dawson-Hughes B, Diez-Perez A, Dufour AB, Eisman JA, Elders PJM, Ferrari S, Fujita Y, Fujiwara S, Glüer CC, Goldshtein I, Goltzman D, Gudnason V, Hall J, Hans D, Hoff M, Hollick RJ, Huismann M, Iki M, Ish-Shalom S, Jones G, Karlsson MK, Khosla S, Kiel DP, Koh WP, Koromani F, Kotowicz MA, Kröger H, Kwok T, Lamy O, Langhammer A, Larijani B, Lippuner K, Mellström D, McGuigan FEA, Merlijn T, Nguyen TV, Nordström A, Nordström P, O'Neill TW, Obermayer-Pietsch B, Ohlsson C, Orwoll ES, Pasco JA, Rivadeneira F, Schei B, Schott AM, Shiroma EJ, Siggeirsdottir K, Simonsick EM, Sornay-Rendu E, Sund R, Swart KMA, Szulc P, Tamaki J, Torgerson DJ, van Schoor NM, van Staa TP, Vila J, Wareham NJ, Wright NC, Yoshimura N, Zillikens MC, Zwart M, Schini M, Vandenput L, Harvey NC, Lorentzon M, Leslie WD, Kanis JA. Family history of fracture and fracture risk: a meta-analysis to update the FRAX® risk assessment tool. *Osteoporos Int*. 2025 Sep;36(9):1725-1741. doi: 10.1007/s00198-025-07607-w.
3. Harvey NC, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, Azagra-Ledesma R, Bager CL, Beaudart C, Bischoff-Ferrari HA, Biver E, Bruyère O, Cauley JA, Center JR, Chapurlat R, Christiansen C, Cooper C, Crandall CJ, Cummings SR, da Silva JAP, Dawson-Hughes B, Diez-Perez A, Dufour AB, Eisman JA, Elders PJM, Ferrari S, Fujita Y, Fujiwara S, Glüer CC, Goldshtein I, Goltzman D, Gudnason V, Hall J, Hans D, Hoff M, Hollick RJ, Huismann M, Iki M, Ish-Shalom S, Jones G, Karlsson MK, Khosla S, Kiel DP, Koh WP, Koromani F, Kotowicz MA, Kröger H, Kwok T, Lamy O, Langhammer A, Larijani B, Lippuner K, McGuigan FEA, Mellström D, Merlijn T, Nguyen TV, Nordström A, Nordström P, O'Neill TW, Obermayer-Pietsch B, Ohlsson C, Orwoll ES, Pasco JA, Rivadeneira F, Schei B, Schott AM, Shiroma EJ, Siggeirsdottir K, Simonsick EM, Sornay-Rendu E, Sund R, Swart KMA, Szulc P, Tamaki J, Torgerson DJ, van Schoor NM, van Staa TP, Vila J, Wareham NJ, Wright NC, Yoshimura N, Zillikens MC, Zwart M, Vandenput L, Lorentzon M, Leslie WD, Kanis JA. Body mass index and subsequent fracture risk: A meta-analysis to update FRAX®. *J Bone Miner Res*. 2025 Aug 8;32:zjaf091.
4. Fuggle N, Rizzoli R, Beaudart C, Cortet B, Curtis EM, Hilgsmann M, Kaufman JM, Veronese N, Albergaria BH, Al-Daghri N, Alkail M, Brandi ML, Bruyère O, Burlet N, Campasano C, Casado E, Cavalier E, Chandran M, Cooper C, D'Amelio P, Dawson-Hughes B, Ebeling PR, Kanis JA, Kurth A, Matijevic R, McCloskey E, McClung M, Mkinsi O, Njeze N, Radermecker RP, Rannou F, Silverman S, Tüzün Ş, Zakraoui L, Reginster JY, Harvey NC. Parathyroid hormone receptor agonists in the management of osteoporosis. *Nat Rev Rheumatol*. 2025 Aug 11.
5. Martens G, Thibaut A, Urhausen A, Tscholl PM, Beaudart C, Romeas T, de Beaumont L, Caron JG, Le Garrec S, Hannouche D, Seil R, Kaux JF, Leclerc S. Sport-Related Concussion Knowledge in French-Speaking Athletes, Coaches, and Health Care Professionals: Results From an International Survey on 2073 Participants. *Clin J Sport Med*. 2025 Aug 6.
6. Hinzpeter EL, Kairies-Schwarz N, Beaudart C, Douxfils J, Nayak D, Hilgsmann M. A Systematic Review of Discrete Choice Experiments on Preferences for COVID-19 Vaccinations. *Patient*. 2025 Jul 10.
7. Douxfils J, Boretti E, Beaudart C, Dogné JM. Letter to the Editor Regarding: Safety of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Due to Menopause: Pooled Analysis of Three Randomized Phase 3 Studies. *Adv Ther*. 2025 Aug;42(8):4089-4091.
8. Scouvenmont M, Humblet F, Bornheim S, Beaudart C, Van Beveren J, Tannoia V, Schaff G, Belii N, Elsen C, Adam S, Schmidt C, Bruyère O. Physical activity scale for the elderly (PASE): Transcultural adaptation into French. *Ann Phys Rehabil Med*. 2025 May 15;68(6):101994.
9. Creinin MD, Douxfils J, Beaudart C, Foidart JM. Errors in the use of the FAERS database to assess the safety of Yasmin. *Eur J Obstet Gynecol Reprod Biol*. 2024.
10. Sharma M, Beaudart C, Clark P, Fujiwara S, Adachi JD, Papaioannou A, Messina OD, Morin SN, Kohlmeier L, Nogues X, Leckie C, Harvey NC, Kanis JA, Reginster JY, Hilgsmann M, Silverman SL. Clinical and demographic factors determining

- patient fracture risk decision point (FRDP): The improving risk communication in osteoporosis (RICO) project. *Osteoporos Int*. 2024 Oct 21.
11. Didembourg M, Locquet M, Raskin L, Tchimchoua BT, Dogné JM, Beaudart C, Duxfils J. Lower reporting of venous thromboembolisms events with natural estrogen-based combined oral contraceptives compared to ethinylestradiol-containing pills: A disproportionality analysis of the Eudravigilance database. *Contraception*. 2024 Oct 17;110:727.
 12. Ladang A, Gendebien AS, Kovacs S, Demonceau C, Beaudart C, Peeters S, Alokail MS, Al-Daghri NM, Le Goff C, Reginster JY, Bruyère O, Cavalier E. Investigation of the Vitamin D Metabolite Ratio (VMR) as a Marker of Functional Vitamin D Deficiency: Findings from the SarcoPhAge Cohort. *Nutrients*. 2024 Sep 24;16(19):3224.
 13. Duxfils J, Beaudart C, Dogné JM. Fezolinetant: a novel nonhormonal therapy for vasomotor symptoms due to menopause requiring a careful evaluation of the benefit-risk balance. *Expert Opin Pharmacother*. 2024 Oct;25(14):1971-1972.
 14. Hinzpeter EL, Nagendra L, Kairies-Schwarz N, Beaudart C, Hilgsmann M. Stated Preferences of At-Risk Populations for the Treatment of Osteoporosis: A Systematic Review. *Patient*. 2024 Nov;17(6):619-634.
 15. Duxfils J, Beaudart C, Dogné JM. Letter to the Editor. *Menopause*. 2024 Aug 1;31(8):734-735.
 16. Duxfils J, Beaudart C, Dogné JM. Fezolinetant for VMS: a balanced view on efficacy and safety needed. *Climacteric*. 2024 Aug;27(4):435.
 17. Duxfils J, Beaudart C, Dogné JM. Letter to the Editor: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials. *Int J Gynaecol Obstet*. 2024 Aug;166(2):905-906.
 18. van Uittert G, Hoogbergen M, Beaudart C, Li N, Boers M, Hilgsmann M. Patients' health related quality of life after massive weight loss reconstruction in the Netherlands. *Expert Rev Pharmacoecon Outcomes Res*. 2024 Aug 21:1-10.
 19. Westbury LD, Harvey NC, Beaudart C, Bruyère O, Cauley JA, Cawthon P, Cruz-Jentoft AJ, Curtis EM, Ensrud K, Fielding RA, Johansson H, Kanis JA, Karlsson MK, Lane NE, Lengelé L, Lorentzon M, McCloskey E, Mellström D, Newman AB, Ohlsson C, Orwoll E, Reginster JY, Ribom E, Rosengren BE, Schousboe JT, Dennison EM, Cooper C; and the International Musculoskeletal Ageing Network. [Predictive value of sarcopenia components for all-cause mortality: findings from population-based cohorts](#). *Aging Clin Exp Res*. 2024 Jun 6;36(1):126. doi: 10.1007/s40520-024-02783-x.
 20. [Duxfils J, Beaudart C, Dogné JM. Letter to the Editor: Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials](#). *Int J Gynaecol Obstet*. 2024 Jun 16. doi: 10.1002/ijgo.15740. Online ahead of print
 21. Duxfils J, Beaudart C, Dogné JM. Totality of evidence refutes neoplasm risk with fezolinetant - Authors' reply. *Lancet*. 2024 May 18;403(10440):1988. doi: 10.1016/S0140-6736(24)00708-6.
 22. Heinz KC, Beaudart C, Willems D, Hilgsmann M. Treatment Preference Research in Atopic Dermatitis: A Systematic Review of Quantitative Studies. *Patient*. 2024 May 9. doi: 10.1007/s40271-024-00698-3. Online ahead of print.
 23. Heinz KC, Beaudart C, Willems D, Wiethoff I, Hilgsmann M. [Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review](#). *Pharmacoeconomics*. 2023 Nov;41(11):1415-1435. doi: 10.1007/s40273-023-01293-4. Epub 2023 Jul 1. PMID: 37392363 Free PMC article.
 24. Calluy E, Beaudart C, Alokail MS, Al-Daghri NM, Bruyère O, Reginster JY, Cavalier E, Ladang A. Confounding factors of the expression of mTBI biomarkers, S100B, GFAP and UCH-L1 in an aging population. *Clin Chem Lab Med*. 2024 Apr 22. doi: 10.1515/ccbm-2024-0194. Online ahead of print.
 25. Millet M, Auroux M, Beaudart C, Demonceau C, Ladang A, Cavalier E, Reginster JY, Bruyère O, Chapurlat R, Rousseau JC. Association of circulating hsa-miRNAs with sarcopenia: the SarcoPhAge study. *Aging Clin Exp Res*. 2024 Mar 14;36(1):70. doi: 10.1007/s40520-024-02711-z.
 26. Pelzer D, Beaudart C, Bornheim S, Maertens de Noordhout B, Schwartz C, Kaux JF. Outcomes of Patients with Lower Limb Loss after Using a Training Prosthesis: A Retrospective Case Series Study. *Healthcare (Basel)*. 2024 Feb 29;12(5):567. doi: 10.3390/healthcare12050567.
 27. Hilgsmann M, Liden B, Beaudart C, Germei E, Hanna A, Joshi M, Koola CP, Stein B, Tonkinson M, Marshall D, Fifer S. HTA Community Perspectives on the Use of Patient Preference Information: Lessons Learned from a Survey with Members of HTA Bodies. *Int J Technol Assess Health Care*. 2024 Mar 5:1-20. doi: 10.1017/S0266462324000138. Online ahead of print.
 28. Pelzer D, Beaudart C, Thibaut A, Bornheim S, Kaux JF. Which factors may influence medium-term quality of life of patients with lower-limb loss? A systematic review of the literature. *Prosthet Orthot Int*. 2024 Feb 13. doi: 10.1097/PXR.0000000000000312. Online ahead of print. PMID: 38345535
 29. Ágh T, Hilgsmann M, Borah B, Beaudart C, Turcu-Stolica A, Manias E, Jakab I, Pednekar P, Zeber J, Peterson AM. Systematic Review of Outcomes for Assessment of Medication Adherence Enhancing Interventions: An ISPOR Special Interest Group Report. *Value Health*. 2023 Nov 10:S1098-3015(23)06192-2.
 30. Duxfils J, Beaudart C, Dogné JM. Risk of neoplasm with the neurokinin 3 receptor antagonist fezolinetant. *Lancet*. 2023 Oct 18:S0140-6736(23)01634-3
 31. Ladang A, Kovacs S, Lengelé L, Locquet M, Beaudart C, Reginster JY, Bruyère O, Cavalier E. Neurofilament-light chains (NF-L), a biomarker of neuronal damage, is increased in patients with severe sarcopenia: results of the SarcoPhAge study. *Aging Clin Exp Res*. 2023 Oct;35(10):2029-2037.
 32. Vandenput L, Johansson H, McCloskey EV, Liu E, Schini M, Åkesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C, Bischoff-Ferrari HA, Biver E, Bruyère O, Cauley JA, Center JR, Chapurlat R, Christiansen C, Cooper C, Crandall CJ, Cummings SR, da Silva JAP, Dawson-Hughes B, Diez-Perez A, Dufour AB, Eisman JA, Elders PJM, Ferrari S, Fujita Y, Fujiwara S, Glüer CC, Goldstein I, Goltzman D, Gudnason V, Hall J, Hans D, Hoff M, Hollick RJ, Huismans M, Iki M, Ish-Shalom S, Jones G, Karlsson MK, Khosla S, Kiel DP, Koh WP, Koromani F, Kotowicz MA, Kröger H, Kwok T, Lamy O, Langhammer A, Larjani B, Lippuner K, McGuigan FEA, Mellström D, Merlijn T, Nguyen TV, Nordström A, Nordström P, O'Neill TW, Obermayer-Pietsch B, Ohlsson C, Orwoll ES, Pasco JA, Rivadeneira F, Schott AM, Shiroma EJ, Siggeirsdóttir K, Simonsick EM, Sornay-Rendu E, Sund R, Swart KMA, Szulc P, Tamaki J, Torgerson DJ, van Schoor NM, van Staa TP, Vila J, Wareham NJ, Wright NC, Yoshimura N, Zillikens M, Zwart M, Harvey NC, Lorentzon M, Leslie WD. A meta-analysis of previous falls and subsequent fracture risk in cohort studies. *Osteoporos Int*. 2024 Mar;35(3):469-494. doi: 10.1007/s00198-023-07012-1. Epub 2024 Jan 17.
 33. Kremer IEH, Beaudart C, Simons J, Plieger H, Schroeder M, Hilgsmann M. Preferences of people living with HIV for injectable and oral antiretroviral treatment in the Netherlands: a discrete choice experiment. *AIDS Care*. 2023 Aug 1:1-10.
 34. Kanis JA, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C, Bischoff-Ferrari HA, Biver E, Bruyère O, Cauley JA, Center JR, Chapurlat R, Christiansen C, Cooper C, Crandall CJ, Cummings SR, da Silva JAP, Dawson-Hughes B, Diez-Perez A, Dufour AB, Eisman JA, Elders PJM, Ferrari S, Fujita Y, Fujiwara S, Glüer CC, Goldstein I, Goltzman D, Gudnason V, Hall J, Hans D, Hoff M, Hollick RJ, Huismans M, Iki M, Ish-Shalom S, Jones G, Karlsson MK, Khosla S, Kiel DP, Koh WP, Koromani F, Kotowicz MA, Kröger H, Kwok T, Lamy O, Langhammer A, Larjani B, Lippuner K, Mellström D, Merlijn T, Nordström A, Nordström P, O'Neill TW, Obermayer-Pietsch B, Ohlsson C, Orwoll ES, Pasco JA, Rivadeneira F, Schott AM, Shiroma EJ, Siggeirsdóttir K, Simonsick EM, Sornay-Rendu E, Sund R, Swart KMA, Szulc P, Tamaki J, Torgerson DJ, van Schoor NM, van Staa TP, Vila J, Wareham NJ, Wright NC, Yoshimura N, Zillikens MC, Zwart M, Vandenput L, Harvey NC, Lorentzon M, Leslie WD. Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX. *Osteoporos Int*. 2023 Aug 11.
 35. Heinz KC, Beaudart C, Willems D, Wiethoff I, Hilgsmann M. Cost-Effectiveness of Emerging Treatments for Atopic Dermatitis: A Systematic Review. *Pharmacoeconomics*. 2023 Jul 1. doi: 10.1007/s40273-023-01293-4.
 36. Moon RJ, Reginster JY, Al-Daghri NM, Thyagarajan JA, Beaudart C, Bruyère O, Burlet N, Chandran M, da Silva MC, Conaghan PG, Dere WH, Diez-Perez A, Hadji P, Halbout P, Hilgsmann M, Kanis JA, McCloskey EV, Ormarsdóttir S, Prieto-Alhambra D, Radermecker RP, Rizzoli R, Al-Saleh Y, Silverman SL, Simon LS, Thomasius F, van Staa TP, Laslop A, Cooper C, Harvey NC. Real-world evidence: new opportunities for osteoporosis research. Recommendations from a Working Group from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Osteoporos Int*. 2023 Jun 23. doi: 10.1007/s00198-023-06827-2
 37. Böger S, van Bergen I, Beaudart C, Cheung KL, Hilgsmann M. Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment. *Expert Rev Pharmacoecon Outcomes Res*. 2023 Jun 14:1-11.
 38. Willems D, Sayed CJ, Van der Zee HH, Ingram JR, Hinzpeter E, Beaudart C, Evers SMAA, Hilgsmann M. [A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States](#). *J Med Econ*. 2023 Mar 23:1-9.
 39. Willems D, Hinzpeter EL, Van der Zee HH, Sayed CJ, Ingram JR, Beaudart C, Evers SMAA, Hilgsmann M. [Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe](#). *Patient*. 2023 Jan 11. doi: 10.1007/s40271-022-00614-7. Online ahead of print.
 40. Li N, Beaudart C, Cauley JA, Ing SW, Lane NE, Reginster JY, Silverman S, Singer AJ, Hilgsmann M. [Cost Effectiveness](#)

- [Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review](#). Pharmacoeconomics. 2023 Apr;41(4):363-391.
41. den Brave M, Beaudart C, de Noordhout BM, Gillot V, Kaux JF. [Effect of robot-assisted gait training on quality of life and depression in neurological impairment: A systematic review and meta-analysis](#). Clin Rehabil. 2023 Jan 22;2692155231152567.
 42. Westbury LD, Beaudart C, Bruyère O, Cauley JA, Cawthon P, Cruz-Jentoft AJ, Curtis EM, Ensrud K, Fielding RA, Johansson H, Kanis JA, Karlsson MK, Lane NE, Lengelé L, Lorentzon M, McCloskey E, Mellström D, Newman AB, Ohlsson C, Orwoll E, Reginster JY, Ribom E, Rosengren BE, Schousboe JT, Shiroma EJ, Harvey NC, Dennison EM, Cooper C; International Musculoskeletal Ageing Network. [Recent sarcopenia definitions-prevalence, agreement and mortality associations among men: Findings from population-based cohorts](#). J Cachexia Sarcopenia Muscle. 2023 Jan 5. doi: 10.1002/jcsm.13160. Online ahead of print.
 43. van Bergen I, Böger S, Beaudart C, Hilgsmann M, Cheung KL. [Beliefs regarding COVID-19 vaccinations of young adults in the United Kingdom: An interview study applying the Integrated Change Model](#). PLoS One. 2022 Dec 6;17(12):e0277109.
 44. Demonceau C, Beaudart C, Reginster JY, Veronese N, Bruyère O. [The interconnection between Covid-19, sarcopenia and lifestyle](#). Maturitas. 2022 Oct 6;S0378-5122(22)00204-3.
 45. Thibaut A, Beaudart C, Martens G, Bornheim S, Kaux J-F. Common bias and challenges in physical and rehabilitation medicine research: How to tackle them. *Frontiers in Rehabilitation Sciences*, 2022. Doi: 10.3389/fresc.2022.873241
 46. Vandenput L, Johansson H, McCloskey EV, Liu E, Åkesson KE, Anderson FA, Azagra R, Bager CL, Beaudart C, Bischoff-Ferrari HA, Biver E, Bruyère O, Cauley JA, Center JR, Chapurlat R, Christiansen C, Cooper C, Crandall CJ, Cummings SR, da Silva JAP, Dawson-Hughes B, Diez-Perez A, Dufour AB, Eisman JA, Elders PJM, Ferrari S, Fujita Y, Fujiwara S, Glüer CC, Goldshtein I, Goltzman D, Gudnason V, Hall J, Hans D, Hoff M, Hollick RJ, Huismans M, Iki M, Ish-Shalom S, Jones G, Karlsson MK, Khosla S, Kiel DP, Koh WP, Koromani F, Kotowicz MA, Kröger H, Kwok T, Lamy O, Langhammer A, Larijani B, Lippuner K, Mellström D, Merlijn T, Nordström A, Nordström P, O'Neill TW, Obermayer-Pietsch B, Ohlsson C, Orwoll ES, Pasco JA, Rivadeneira F, Schei B, Schott AM, Shiroma EJ, Siggeirsdottir K, Simonsick EM, Sornay-Rendu E, Sund R, Swart KMA, Szulc P, Tamaki J, Torgerson DJ, van Schoor NM, van Staa TP, Vila J, Wareham NJ, Wright NC, Yoshimura N, Zillikens MC, Zwart M, Harvey NC, Lorentzon M, Leslie WD, Kanis JA. Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. *Osteoporos Int*. 2022 May 31. doi: 10.1007/s00198-022-06435-6
 47. Dardenne N, Locquet M, Diep AN, Gilbert A, Delrez S, Beaudart C, Brabant C, Ghuyssen A, Donneau AF, Bruyère O. [Clinical prediction models for diagnosis of COVID-19 among adult patients: a validation and agreement study](#). BMC Infect Dis. 2022 May 14;22(1):464. doi: 10.1186/s12879-022-07420-4.
 48. Veronese N, Custodero C, Demurtas J, Smith L, Barbagallo M, Maggi S, Cella A, Vanacore N, Aprile PL, Ferrucci L, Pilotto A; Special Interest Group in Systematic Reviews of the European Geriatric Medicine Society (EuGMS); Special Interest Group in Meta-analyses and Comprehensive Geriatric Assessment of the European Geriatric Medicine Society (EuGMS). [Comprehensive geriatric assessment in older people: an umbrella review of health outcomes](#). Age Ageing. 2022 May 1;51(5):afac104. doi: 10.1093/ageing/afac104.
 49. Horlait G, Beaudart C, Bougard L, Bornheim S, Colson C, Misset B, Bruyère O, Boustani M, Rousseau AF. [Post-intensive care screening: French translation and validation of the Healthy Aging Brain Care-Monitor, hybrid version](#). Health Qual Life Outcomes. 2022 Apr 2;20(1):59. doi: 10.1186/s12955-022-01967-1.
 50. Brabant C, Geerinck A, Beaudart C, Tirelli E, Geuzaine C, Bruyère O. [Exposure to magnetic fields and childhood leukemia: a systematic review and meta-analysis of case-control and cohort studies](#). Rev Environ Health. 2022 Mar 15. doi: 10.1515/reveh-2021-0112. Online ahead of print.
 51. Rohde L, Mossialos E, Beaudart C, Joos A, Heikkinen I, Holland S, Hilgsmann M. [Discrete choice experiment to investigate preferences for incentives to promote antimicrobial research and development](#). J Glob Antimicrob Resist. 2022 Feb 13;29:42-48. doi: 10.1016/j.jgar.2022.02.006.
 52. Chiwire P, Beaudart C, Evers SM, Mahomed H, Hilgsmann M. [Enhancing Public Participation in Public Health Offerings: Patient Preferences for Facilities in the Western Cape Province Using a Discrete Choice Experiment](#). Int J Environ Res Public Health. 2022 Jan 5;19(1):590.
 53. Sanfilippo D, Beaudart C, Gaillard A, Bornheim S, Bruyère O, Kaux JF. [What Are the Main Risk Factors for Lower Extremity Running-Related Injuries? A Retrospective Survey Based on 3669 Respondents](#). Orthop J Sports Med. 2021 Nov 18;9(11):23259671211043444. doi: 10.1177/23259671211043444.
 54. Thibaut A, Beaudart C, Maertens de Noordhout B, Geers S, Kaux JF, Pelzer D. [Impact of microprocessor prosthetic knee on mobility and quality of life in patients with lower limb amputation: a systematic review of the literature](#). Eur J Phys Rehabil Med. 2022 Feb 11. doi: 10.23736/S1973-9087.22.07238-0.
 55. Lengelé L, Locquet M, Moutschen M, Beaudart C, Kaux JF, Gillain S, Reginster JY, Bruyère O. [Frailty but not sarcopenia nor malnutrition increases the risk of developing COVID-19 in older community-dwelling adults](#). Aging Clin Exp Res. 2021 Oct 23;1-12. doi: 10.1007/s40520-021-01991-z.
 56. Médéa Locquet , Anh Nauvet Diep, Charlotte Beaudart, Nadia Dardenne, Christian Brabant, Olivier Bruyère , Anne-Françoise Donneau. A systematic review of prediction models to diagnose COVID-19 in adults admitted to healthcare centers. Arch Public Health. 2021 Jun 18;79(1):105.
 57. Anton Geerinck, Bess Dawson-Hughes, Charlotte Beaudart, Médéa Locquet, Jean-Yves Reginster, Olivier Bruyère. Assessment of the performance of the SarQoL ® questionnaire in screening for sarcopenia in older people. Aging Clin Exp Res. 2021 Aug;33(8):2149-2155.
 58. M Locquet, F Bonnard, C Beaudart, C Coendo, S Gillain, J-Y Reginster, O Bruyère. An Assessment of the Toulouse Saint Louis University Mini Falls Assessment Tool to Predict Incident Falls among Older Adults Residing in Nursing Homes: A 6-Month Prospective Study J Nutr Health Aging. 2021;25(7):933-937.
 59. Laetitia Lengelé, Olivier Bruyère, Charlotte Beaudart, Jean-Yves Reginster, Médéa Locquet. Malnutrition, assessed by the Global Leadership Initiative on Malnutrition (GLIM) criteria but not by the mini nutritional assessment (MNA), predicts the incidence of sarcopenia over a 5-year in the SarcoPhAge cohort. Aging Clin Exp Res. 2021 Jun;33(6):1507-1517.
 60. Geerinck A, Beaudart C, Reginster JY, Locquet M, Monseur C, Gillain S, Bruyère O. Development and validation of a short version of the Sarcopenia Quality of Life questionnaire: the SF-SarQoL. Qual Life Res. 2021 Mar 30. doi: 10.1007/s11136-021-02823-3.
 61. Erdogan T, Eris S, Avci S, Oren MM, Kucukdagli P, Kilic C, Beaudart C, Bruyère O, Karan MA, Bahat G. Sarcopenia quality-of-life questionnaire (SarQoL)®: translation, cross-cultural adaptation and validation in Turkish. Aging Clin Exp Res. 2021 Feb 4. doi: 10.1007/s40520-020-01780-0. Online ahead of print
 62. Veronese N, Demurtas J, Smith L, Reginster JY, Bruyère O, Beaudart C, Honvo G, Maggi S; on behalf of the European Geriatric Medicine Society Special Interest Groups in Systematic Reviews and Meta-Analyses and Arthritis. Glucosamine sulphate: an umbrella review of health outcomes. Ther Adv Musculoskelet Dis. 2020 Dec 26;12:1759720X20975927. doi: 10.1177/1759720X20975927. eCollection 2020.
 63. Lengelé L, Bruyère O, Beaudart C, Reginster JY, Locquet M. Impact of Malnutrition Status on Muscle Parameter Changes over a 5-Year Follow-Up of Community-Dwelling Older Adults from the SarcoPhAge Cohort. Nutrients. 2021 Jan 28;13(2):407. doi: 10.3390/nu13020407
 64. Dangouloff T, Botty C, Beaudart C, Servais L, Hilgsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021 Jan 23;16(1):47. doi: 10.1186/s13023-021-01695-7.
 65. Audrey Neuprez, Jean-François Kaux, Médéa Locquet, Charlotte Beaudart, Jean-Yves Reginster. The presence of erosive joints is a strong predictor of radiological progression in hand osteoarthritis: results of a 2-year prospective follow-up of the Liège Hand Osteoarthritis Cohort (LIHOC). Arthritis Res Ther. 2021 Jan 6;23(1):12. doi: 10.1186/s13075-020-02390-x.
 66. Stany Perkisas, Sophie Bastijns, Stéphane Baudry, Jürgen Bauer, Charlotte Beaudart, David Beckwée, Alfonso Cruz-Jentoft, et al. Application of ultrasound for muscle assessment in sarcopenia: 2020 SARCUS update. Eur Geriatr Med. 2021 Jan 2. doi: 10.1007/s41999-020-00433-9. Online ahead of print.
 67. Leclercq V, Hilgsmann M, Parisi G, Beaudart C, Tirelli E, Bruyère O. Best-worst scaling identified adequate statistical methods and literature search as the most important items of AMSTAR2 (A measurement tool to assess systematic reviews). J Clin Epidemiol. 2020 Dec;128:74-82.
 68. Bornheim S, Thibaut A, Beaudart C, Maquet P, Croisier JL, Kaux JF. Evaluating the Effects of tDCS in Stroke Patients Using Functional Outcomes: A Systematic Review. Disabil Rehabil. 2020 May 12;1-11
 69. Tooth C, Gofflot A, Schwartz C, Croisier JL, Beaudart C, Bruyère O, Forthomme B. Risk factors of overuse shoulder injuries in overhead athletes: a systematic review. Sports Health. 2020 Sep/Oct;12(5):478-487.
 70. Hilgsmann M, Dennison E, Beaudart C, Herrero-Beaumont G, Branco J, Bruyère O, Conaghan PG, Cooper C, Al-Daghri N,

- Jiwa F, Lems W, Pinto D, Rizzoli R, Thomas T, Uebelhart D, Veronese N, Reginster JY. A discrete-choice experiment to assess patients' preferences for osteoarthritis treatment: An ESCO working group. *Semin Arthritis Rheum*. 2020 Oct;50(5):859-866.
71. Ferrer Soler C, Cuvelier C, Hars M, Herrmann FR, Charpiot A, Ducharme Wiczorkiewicz C, Bruyère O, Beaudart C, Zekry D, Gold G, Trombetti A. Validation of the Perform-FES: a new fear of falling scale for hospitalized geriatric patients. *Aging Clin Exp Res*. 2020 Oct 15.
 72. Sanchez-Rodriguez D, Beaudart C, Lengelé L, Reginster JY, Bruyère O. The role of Nutrition in Bone Health. (Submitted)
 73. Ladang A, Beaudart C, Locquet M, Reginster JY, Bruyère O, Cavalier E. [Evaluation of a Panel of MicroRNAs that Predicts Fragility Fracture Risk: A Pilot Study](#). *Calcif Tissue Int*. 2019 Nov 15.
 74. V. Leclercq, C. Beaudart, S. Ajamieh, E. Tirelli, O. Bruyère. Methodological quality of meta-analyses indexed in PsycINFO: leads for enhancements: a meta-epidemiological study. *BMJ Open*. 2020 Aug 3;10(8):e036349.
 75. V Leclercq, C Beaudart, E Tirelli, O Bruyère. [PSYCHOMETRIC MEASUREMENTS OF AMSTAR 2 IN A SAMPLE OF META-ANALYSES INDEXED IN PSYCINFO](#). *J Clin Epidemiol*. 2019 Nov 4. pii: S0895-4356(19)30786-3.
 76. Veronese N, Torbahn G, Demurtas J, Beaudart C, Soysal P, Marengoni A, Shenkin SD, Petrovic M, Sieber CC, Cherubini A, Smith L, Maggi S. Interest in meta-research in geriatric medicine: a survey of members of the European Geriatric Medicine Society. *Eur Geriatr Med*. 2020 Jul 23.
 77. Sanchez-Rodriguez D, Bergmann P, Body JJ, Cavalier E, Gielen E, Goemaere S, Lapauw B, Laurent MR, Rozenberg S, Honvo G, Beaudart C, Bruyère O. The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women. *Maturitas*. 2020 Sep;139:69-89.
 78. Dzhus M, Dzhus M, Masnyi M, Kulyk M, Mostbauer H, Ivashkevich O, Boyko Y, Cherchenko K, Geerinck A, Reginster JY, Bruyère O, Beaudart C. Cross-sectional Evaluation of the Sarcopenia Quality of Life (SarQoL) Questionnaire: Translation and Validation of its Psychometric Properties. *Ann Geriatr Med Res*. 2020 Jun;24(2):139-147.
 79. Reginster JY, Beaudart C, Al-Daghri N, Avouac B, Bauer J, Bere N, Bruyère O, Cerrera F, Cesari M, Rosa MM, Cooper C, Cruz Jentoft AJ, Dennison E, Geerinck A, Gielen E, Landi F, Laslop A, Maggi S, Prieto Yerro MC, Rizzoli R, Sundseth H, Sieber C, Trombetti A, Vellas B, Veronese N, Visser M, Vlaskovska M, Fielding RA. Update on the ESCO recommendation for the conduct of clinical trials for drugs aiming at the treatment of sarcopenia in older adults. *Aging Clin Exp Res*. 2020 Jul 31.
 80. Demurtas J, Celotto S, Beaudart C, Sanchez-Rodriguez D, Balci C, Soysal P, Solmi M, Celotto D, Righi E, Smith L, Lopcalco PL, Noventa V, Michel JP, Torbahn G, Di Gennaro F, Pizzol D, Veronese N, Maggi S. The efficacy and safety of influenza vaccination in older people: An umbrella review of evidence from meta-analyses of both observational and randomized controlled studies. *Ageing Res Rev*. 2020 Sep;62:101118.
 81. Hilgsmann M, Beaudart C, Bruyère O, Biver E, Bauer J, Cruz-Jentoft AJ, Gesmundo A, Goisser S, Landi F, Locquet M, Maggi S, Rizzoli R, Rolland Y, Vaquero N, Cooper C, Reginster JY; European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). [Outcome Priorities for Older Persons With Sarcopenia](#). *J Am Med Dir Assoc*. 2019 Oct 28. pii: S1525-8610(19)30643-7.
 82. Locquet M, Beaudart C, Durieux N, Reginster JY, Bruyère O. [Relationship between the changes over time of bone mass and muscle health in children and adults: a systematic review and meta-analysis](#). *BMC Musculoskelet Disord*. 2019 Sep 14;20(1):429. doi: 10.1186/s12891-019-2752-4.
 83. Cimpaye O, Louis R, Darcis G, Beaudart C, Meuris C. [\[Application of the Upper Council of Health recommendations in the respiratory isolation of patients with pulmonary tuberculosis at Liège University Hospital.\]](#) *Rev Med Liege*. 2019 Sep;74(9):465-470. French.
 84. Hajaoui M, Locquet M, Beaudart C, Reginster JY, Petermans J, Bruyère O. [Sarcopenia: Performance of the SARC-F Questionnaire According to the European Consensus Criteria, EWGSOP1 and EWGSOP2](#). *J Am Med Dir Assoc*. 2019 Sep;20(9):1182-1183.
 85. Leclercq V, Beaudart C, Ajamieh S, Rabenda V, Tirelli E, Bruyère O. [Meta-analyses indexed in PsycINFO had a better completeness of reporting when they mention PRISMA](#). *J Clin Epidemiol*. 2019 Nov;115:46-54. doi: 10.1016/j.jclinepi.2019.06.014. Epub 2019 Jun 26. Review.
 86. Honvo G, Leclercq V, Geerinck A, Thomas T, Veronese N, Charles A, Rabenda V, Beaudart C, Cooper C, Reginster JY, Bruyère O. [Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis](#). *Drugs Aging*. 2019 Apr;36(Suppl 1):45-64.
 87. Beckwée D, Delaere A, Aelbrecht S, Baert V, Beaudart C, Bruyère O, de Saint-Hubert M, Bautmans I. [Exercise Interventions for the Prevention and Treatment of Sarcopenia. A Systematic Umbrella Review](#). *J Nutr Health Aging*. 2019;23(6):494-502. doi: 10.1007/s12603-019-1196-8.
 88. Geerinck A, Beaudart C, Salvan Q, Van Beveren J, D'Hooghe P, Bruyère O, Kaux JF. [French translation and validation of the Cumberland Ankle Instability Tool, an instrument for measuring functional ankle instability](#). *Foot Ankle Surg*. 2019 May 9. pii: S1268-7731(19)30065-7.
 89. Geerinck A, Alekna V, Beaudart C, Bautmans I, Cooper C, De Souza Orlandi F, Konstantynowicz J, Montero-Erasquin B, Topinková E, Tsekoura M, Reginster JY, Bruyère O. [Standard error of measurement and smallest detectable change of the Sarcopenia Quality of Life \(SarQoL\) questionnaire: An analysis of subjects from 9 validation studies](#). *PLoS One*. 2019 Apr 29;14(4):e0216065.
 90. Locquet M, Willems T, Specque C, Beaudart C, Bruyère O, Van Beveren J, Dardenne N, Reginster JY, Kaux JF. [Cross-cultural adaptation, translation, and validation of the functional assessment scale for acute hamstring injuries \(FASH\) questionnaire for French-speaking patients](#). *Disabil Rehabil*. 2019 Jan 22:1-7.
 91. Locquet M, Beaudart C, Petermans J, Reginster JY, Bruyère O. [EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences](#). *J Am Med Dir Assoc*. 2019 Mar;20(3):384-385.
 92. M. Hilgsmann, D. Pinto, E. Dennison, N. Al-Daghri, C. Beaudart, J. Branco, O. Bruyère, PG. Conaghan, C. Cooper, G. Herrero-Beaumont, F. Jiwa, W. Lems, R. Rizzoli, T. Thomas, N. Veronese, JY. Reginster. *Patients' preferences for osteoarthritis treatment: the value of stated-preference studies*. *Aging Clinical and Experimental Research*. *Aging Clin Exp Res*. 2019 Jan;31(1):1-3.
 93. Bruyère O, Beaudart C, Ethgen O, Reginster JY, Locquet M. [The health economics burden of sarcopenia: a systematic review](#). *Maturitas*. 2019 Jan;119:61-69. doi: 10.1016/j.maturitas.2018.11.003. Epub 2018 Nov 12. Review.
 94. Geerinck A, Scheppers A, Beaudart C, Bruyère O, Vandebussche W, Bautmans R, Delye S, Bautmans I. [Translation and validation of the Dutch SarQoL®, a quality of life questionnaire specific to sarcopenia](#). *J Musculoskelet Neuronal Interact*. 2018 Dec 1;18(4):463-472.
 95. Locquet M, Beaudart C, Reginster JY, Bruyère O. [Association Between the Decline in Muscle Health and the Decline in Bone Health in Older Individuals from the SarcoPhAge Cohort](#). *Calcif Tissue Int*. 2018 Dec 3. doi: 10.1007/s00223-018-0503-4. [Epub ahead of print]
 96. Tsekoura M, Billis E, Gliatis J, Tsepis E, Matzaroglou C, Sakkas GK, Beaudart C, Bruyère O, Tyllianakis M, Panagiotopoulos E. [Cross cultural adaptation of the Greek sarcopenia quality of life \(SarQoL\) questionnaire](#). *Disabil Rehabil*. 2018 Nov 19:1-7. doi: 10.1080/09638288.2018.1514076. [Epub ahead of print]
 97. Konstantynowicz J, Abramowicz P, Glinkowski W, Taranta E, Marcinowicz L, Dymitrowicz M, Reginster JY, Bruyère O, Beaudart C. [Polish Validation of the SarQoL®, a Quality of Life Questionnaire Specific to Sarcopenia](#). *J. Clin Med*. 2018 Oct 4;7(10). pii: E323. doi: 10.3390/jcm7100323.
 98. Locquet M, Beaudart C, Delandsheere L, Reginster JY, Bruyère O. [Subjective Sleep Quality among Sarcopenic and Non-Sarcopenic Older Adults: Results from the SarcoPhAge Cohort](#). *J Frailty Aging*. 2018;7(3):176-181. doi: 10.14283/jfa.2018.13.
 99. De Spiegeleer A, Beckwée D, Bautmans I, Petrovic M; Sarcopenia Guidelines [Pharmacological Interventions to Improve Muscle Mass, Muscle Strength and Physical Performance in Older People: An Umbrella Review of Systematic Reviews and Meta-analyses](#). Development group of the Belgian Society of Gerontology and Geriatrics (BSGG).
 100. Locquet M, Beaudart C, Hajaoui M, Petermans J, Reginster JY, Bruyère O. [Three-Year Adverse Health Consequences of Sarcopenia in Community-Dwelling Older Adults According to 5 Diagnosis Definitions](#). *J Am Med Dir Assoc*. 2019 Jan;20(1):43-46.e2. doi: 10.1016/j.jamda.2018.06.004. Epub 2018 Jul 19.
 101. M. Locquet, C. Beaudart, O. Bruyère, JA. Kanis, L. Delandsheere, JY. Reginster. Bone health assessment in older people with or with muscle health impairment. *Osteoporos Int*. 2018 Feb 14.
 102. M. Locquet, C. Beaudart, J.Y. Reginster, J. Petermans, O. Bruyère. Comparison of the performance of five screening methods for sarcopenia. *Clinical Epidemiology*, 2017 Dec 29;10:71-82. doi: 10.2147/CLEP.S148638. eCollection 2018.
 103. F. Buckinx, JY. Reginster, T. Bruinois, C. Lenaerts, C. Beaudart, JL. Croisier, J. Petermans, O. Bruyère. [Prevalence of sarcopenia in a population of nursing home residents according to their frailty status: results of the SENIOR cohort](#). *J Musculoskelet Neuronal Interact*. 2017 Sep 1;17(3):209-217.

104. O. Bruyère, F. Buckinx, C. Beaudart, JY. Reginster, J. Bauer, T. Cederholm, A. Cherubini, C. Cooper, AJ. Cruz Jentoft, F. Landi, S. Maggi, R. Rizzoli, AA. Sayer, C. Sieber, B. Vellas, M. Cesari, ESCEO and the EUGMS frailty working group. [How clinical practitioners assess frailty in their daily practice: an international survey](#). *Aging Clin Exp Res*. 2017 Oct;29(5):905-912.
105. M. Locquet, C. Beaudart, JY. Reginster, J. Petermans, S. Gillain, A. Quabron, J. Slomian, F. Buckinx, O. Bruyère. Prevalence of concomitant bone and muscle wasting in elderly women from the SarcoPhAge cohort: preliminary results. *The Journal of Frailty & Aging*. 2017;6(1):18-23.
106. F. Buckinx, JY. Reginster, J. Petermand, JL. Croisier, C. Beaudart T. Brunois, O. Bruyère. [Relationship between frailty, physical performance and quality of life among nursing home residents: the SENIOR cohort](#). *Aging Clin Exp Res*. 2016 Dec;28(6):1149-1157.
107. M. Locquet, C. Beaudart, R. Larbuisson, F. Buckinx, JF. Kaux, JY. Reginster, O. Bruyère. Self-medication practice among amateur runners: prevalence and associated factors. *J Sports Sci Med*. 2016 Jun; 15(2): 387-388.
108. O. Bruyère, C. Beaudart, J-Y. Reginster, F. Buckinx, D. Schoene, V. Hirani, C. Cooper, J.A. Kanis, R. Rizzoli; E. McCloskey, T. Cederholm, A. Cruz-Jentoft, E. Freiburger. Assessment of muscle mass, muscle strength and physical performance in clinical practice: An international survey. *European Geriatric Medicine* (2016) 243-246.
109. JF. Kaux, F. Delvaux, J. Oppong, F. Buckinx, C. Beaudart, JL. Croisier, B. Forthomme, O. Bruyère, JM. Crielaar. Cross-cultural adaptation of the VISA-P questionnaire for French-speaking patients with patellar tendinopathy. *J Orthop Sports Phys Ther*. 2016 May;46(5):384-90.
110. JF. Kaux, F. Delvaux, J. Oppong, F. Buckinx, C. Beaudart, JL. Croisier, B. Forthomme, O. Bruyère, JM. Crielaar. Translation, validity and reliability of the French translation of the VISA-A questionnaire for Achilles tendinopathy. *Disabil Rehabil*. 2016 Dec;38(26):2593-9
111. E. Cavalier, C. Beaudart, F. Buckinx, O. Bruyère, J.-Y. Reginster. Critical analytical evaluation of promising markers for sarcopenia. *European geriatric medicine* (2016) 239-242
112. O. Bruyère, C. Beaudart, M. Locquet, F. Buckinx, J. Petermans, JY. Reginster. Sarcopenia as a public health problem. *European geriatric medicine* (2016) 272-275.
113. B. Fox, T. Henwood, L. Schaap, O. Bruyère, JY. Reginster, C. Beaudart, F. Buckinx, H. Roberts, C. Cooper, A. Cherubini, G. Dell'Aquila, M. Maggio, S. Volpato. Adherence to a standardized protocol for measuring grip strength and appropriate cut-off values in adults over 65 years with sarcopenia: a systematic review protocol. *The JBI Database of Systematic Reviews and Implementation Reports*. 2015 Oct;13(10):50-9.
114. F. Buckinx, JL. Croisier, JY. Register, N. Dardenne, C. Beaudart, J. Slomian, S. Léonard, O. Bruyère. Reliability of muscle strength measures obtained with a hand-held dynamometer in an elderly population. *Clin Physiol Funct Imaging*. 2017 May;37(3):332-340.
115. J-Y Reginster, C. Beaudart, F. Buckinx, O. Bruyère. Osteoporosis and sarcopenia: two diseases or one? *Curr Opin Clin Nutr Metab Care*. 2016 Jan;19(1):31-6
116. JY. Reginster, A. Neuprez, MP. Lecart, C. Beaudart, F. Buckinx, J. Slomian, O. Bruyère. Ostéoporose et médecine personnalisée. *Revue Médicale de Liège*. 2015, 70 – 321-324.
117. J. Slomian, J-Y. Reginster, U. Gaspard, S. Streeel, C. Beaudart, G. Appelboom, F. Buckinx, O. Bruyère. Exploring the interest in and the usage of the Internet among patients eligible for osteoporosis screening. *Calcif Tissue International*. <http://www.ncbi.nlm.nih.gov/pubmed/25837844> 2015 Jun;96(6):518-26.
118. F. Buckinx, J-Y. Reginster, N. Dardenne, JL. Croisier, JF. Kaux, C. Beaudart, J. Slomian, O. Bruyère. Concordance between muscle mass assessed by bioelectrical impedance analysis and by dual energy X-ray absorptiometry. *BMC Musculoskelet Disord*. 2015 Mar 18;16(1):60.
119. F. Buckinx, C. Beaudart, J. Slomian, D. Maquet, M. Demonceau, S. Gillain, J. Petermans, JY. Reginster, O. Bruyère. [Added value of a triaxial accelerometer assessing gait parameters to predict falls and mortality among nursing home residents: A two-year prospective study](#). *Technol Health Care*. 2015 Jan 1;23(2):195-203.
120. JY. Reginster, A. Neuprez, N. Dardenne, C. Beaudart, O. Bruyère. Efficacy and safety of currently marketed anti-osteoporosis medications. Best Practice and Research Clinical Endocrinology and Metabolism. *Best Pract Res Clin Endocrinol Metab*. 2014 Dec;28(6):809-834
121. O. Bruyère, E. Cavalier, JC. Souberbielle, HA. Bischoff-Ferrari, C. Beaudart, F. Buckinx, JY. Reginster, R. Rizzoli. Effects of vitamin D in the elderly population: current status and perspectives. *Archives of Public Health*, 2014 ; 72:32-42.
122. JY. Reginster, A. Neuprez, C. Beaudart, MP. Lecart, N. Sarlet, S. Disteché, O. Bruyère. Antiresorptive drugs beyond bisphosphonates and selective estrogen receptor modulators for the management of osteoporosis. *Drugs Aging*. 2014 Jun;31(6):413-24.
123. O. Bruyère, J. Slomian, C. Beaudart, F. Buckinx, E. Cavalier. http://www.ncbi.nlm.nih.gov/pubmed?term=Gillain%20S%5BAuthor%5D&cauthor=true&cauthor_uid=24784761. Gillain, J, Petermans, JY. Reginster. Prevalence of vitamin D inadequacy in European women aged over 80 years. *Arch Gerontol Geriatr*. 2014 Apr 5. pii: S0167-4943(14)00040-5.
124. JY. Reginster, A. Neuprez, C. Beaudart, F. Buckinx, J. Slomian, S. Disteché, O. Bruyère. Bone forming agents for the management of osteoporosis. *Painmanagement*. 2014 Jun;56(2):97-114.
125. F. Buckinx, C. Beaudart, D. Maquet, M. Demonceau, JM. Crielaard, JY. Reginster, O. Bruyère. Evaluation of the impact of 6-month training by whole body vibration on the risk of falls among nursing home residents, observed over a 12-month period: a single blind, randomized controlled trial. *Aging Clin Exp Res*. 2014 Aug;26(4):369-76
126. O. Bruyère, M. Demoulin, C. Beaudart, J. C. Hill, D. Maquet, S. Genevay, G. Mahieu, J-Y. Reginster, J-M. Crielaard, C. Demoulin. Validity and reliability of the French version of the STaT Back Screening Tool for patients with low back pain. *Spine*, 2014 Jan 15;39(2):E123-8.
127. O. Bruyère, V. Rabenda, F. Buckinx, C. Beaudart, JY. Reginster. Changes in the structure and the symptoms of the osteoarthritic knee and prediction of future knee replacement over an 8-year follow-up period. *Calcified Tissue International*, 2013, 93(6).
128. S. Gillain, L. Elbous, C. Beaudart, O. Bruyère, J. Petermans. Les chutes de la personne âgée. *Revue Médicale de Liège*. 69(5-6),258-264
129. J-Y. Reginster, C. Beaudart, A. Neuprez, O. Bruyère. Strontium ranelate in the treatment of knee osteoarthritis. New insights and emerging clinical evidence. *Therapeutic Advances in Musculoskeletal Disease*, 2013. 2013 Oct;5(5):268-76.
130. R. Rizzoli, J-Y. Reginster, J-F. Arnal, Ivan Bautmans, C. Beaudart, H. Bischoff-Ferrari, E. Biver, S. Boonen, ML. Brandi, A. Chines, C. Cooper, S. Dahlin-Ivanoff, S. Epstein, J. Kanis, R.A. Fielding, B. Goodpaster, A. Laslop, V. Malafarina, L. Rodriguez Mañas, B. H. Mitlak, R.O. Oreffo, J. Petermans, K. Reid, Y. Rolland, A. Alhie Sayer, Y. Tsouderos, M. Visser, O. Bruyère. Quality of Life in Sarcopenia and Frailty. *Calcif Tissue International*. 2013 Aug;93(2):101-20
131. V. Rabenda, D. Nicolet, C. Beaudart, O. Bruyère, J-Y. Reginster. Relationship between use of antidepressants and risk of fractures: a meta-analysis. *Osteoporosis International*, 2013, 24 :121-137.

Projects

Memberships

- From 2025 : Membre au sein de l'école doctorale "Sciences médicales" of the Fonds National de la Recherche Scientifique (FNRS).
- From 2025 : Member of the "Collège des Jeunes Chercheurs » of the « Académie Royale de Médecine de Belgique »
- From 2025: Senior Advisor of the World Health Organisation (WHO) Bone Health Expert Working Group (BOHEG) group developed within the 5-year WHO Collaborating Centre for Public Health aspects of musculoskeletal health and ageing agreement
- From 2025: Co-founder of the *Emerging Scientist Network* of the Osteoporosis International Foundation (IOF)
- From 2025: Member of the Scientist Committee of Sciensano, Belgium.
- From 2025: Board Member of the Belgian Bone Club (BBC)
- From 2025: Co-leader of the Special Interest Group (SIG) systematic reviews and meta-analyses of the European Geriatric Medicine Society (EUGMS)
- From 2024: Board Member of the Belgian Ageing Muscle Society (BAMS)
- From 2024: Member of the Global Leadership Initiative on Sarcopenia (GLIS) and co-leader of the GLIS working Group on outcomes of sarcopenia
- From 2023: Member of the International Conference on Frailty and Sarcopenia Research (ICSFR) Task Force on Geroscience

- Pre-Clinical and Clinical Trials
- From 2020: Scientific Board Member of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

Other Relevant Information